Home
PASG
PASG News

Latest Passage Bio Inc. (PASG) News on July 5, 2025

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

GlobeNewswire

13 days ago

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

GlobeNewswire

2 months ago

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Zacks

4 months ago

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

MT Newswires

4 months ago

Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire

4 months ago

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

GlobeNewswire

6 months ago

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Simply Wall St.

6 months ago

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio assumed with an Outperform at Wedbush

TipRanks

7 months ago

Passage Bio assumed with an Outperform at Wedbush

MT Newswires

7 months ago

Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

MT Newswires

7 months ago

Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

Passage Bio Achieves Milestones in Gene Therapy Trials

TipRanks

8 months ago

Passage Bio Achieves Milestones in Gene Therapy Trials

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire

8 months ago

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

GlobeNewswire

8 months ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

GlobeNewswire

8 months ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

GuruFocus.com

9 months ago

Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc

GuruFocus.com

10 months ago

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

GlobeNewswire

10 months ago

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Passage Bio Welcomes Tom Kassberg to Board of Directors

GlobeNewswire

10 months ago

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

10 months ago

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire

a year ago

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Passage Bio to Participate in Upcoming Investor Conferences

Jim Wilson, prominent gene therapy researcher, to depart UPenn

BioPharma Dive

a year ago

Jim Wilson, prominent gene therapy researcher, to depart UPenn

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

GlobeNewswire

a year ago

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Passage Bio targets FDA to greenlight ALS gene therapy trial

Clinical Trials Arena

a year ago

Passage Bio targets FDA to greenlight ALS gene therapy trial

Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth?

Simply Wall St.

a year ago

Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth?

MT Newswires

a year ago

Passage Bio Receives Positive Opinion From FDA on Plan to Expand Frontotemporal Dementia Drug Trial

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

GlobeNewswire

a year ago

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

a year ago

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

GlobeNewswire

a year ago

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire

a year ago

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

GlobeNewswire

a year ago

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know

Zacks

a year ago

Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

GlobeNewswire

a year ago

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

GlobeNewswire

a year ago

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Passage Bio to Participate in Upcoming Investor Conferences

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Simply Wall St.

a year ago

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

7 Analyst-Backed Stocks With Promising 10-Bagger Potential

InvestorPlace

a year ago

7 Analyst-Backed Stocks With Promising 10-Bagger Potential

Earnings Preview: Legget & Platt (LEG) Q4 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Legget & Platt (LEG) Q4 Earnings Expected to Decline

Strength Seen in WillScot (WSC): Can Its 5.0% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in WillScot (WSC): Can Its 5.0% Jump Turn into More Strength?

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Golden Matrix Reports Fiscal 2023 Financial Results With Record Revenues of $44.2 Million

NewMediaWire

a year ago

Golden Matrix Reports Fiscal 2023 Financial Results With Record Revenues of $44.2 Million

CPSI Announces Divestment of American HealthTech to PointClickCare

Business Wire

a year ago

CPSI Announces Divestment of American HealthTech to PointClickCare

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable

Simply Wall St.

a year ago

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable

abrdn U.S. Closed End Funds Announce Distribution Payment Details

ACCESSWIRE

a year ago

abrdn U.S. Closed End Funds Announce Distribution Payment Details

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

CNW Group

a year ago

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

Baillie Gifford Trims Position in Codexis Inc

GuruFocus.com

a year ago

Baillie Gifford Trims Position in Codexis Inc

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results

GlobeNewswire

a year ago

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results

Ken Langone Just Invested $3 Million in This Struggling Green Stock

Barrons.com

a year ago

Ken Langone Just Invested $3 Million in This Struggling Green Stock

Lands’ End Launches Exclusive Women’s Swimwear Collection at Target

GlobeNewswire

2 years ago

Lands’ End Launches Exclusive Women’s Swimwear Collection at Target

Burning Rock Announces Receipt of Notification from NASDAQ

GlobeNewswire

2 years ago

Burning Rock Announces Receipt of Notification from NASDAQ

7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight

InvestorPlace

2 years ago

7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight

5 Beaten-Down Chinese Stocks Set to Rebound in 2024

Zacks

2 years ago

5 Beaten-Down Chinese Stocks Set to Rebound in 2024

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

GlobeNewswire

2 years ago

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Investors in Natural Health Trends (NASDAQ:NHTC) have unfortunately lost 49% over the last five years

Simply Wall St.

2 years ago

Investors in Natural Health Trends (NASDAQ:NHTC) have unfortunately lost 49% over the last five years

First Bank (FRBA) Surges 5.1%: Is This an Indication of Further Gains?

Zacks

2 years ago

First Bank (FRBA) Surges 5.1%: Is This an Indication of Further Gains?

GlobeNewswire

2 years ago

trivago Unveils a Bold Brand Refresh and AI powered TV Ads

Central Valley Community Bancorp (CVCY) Soars 6.4%: Is Further Upside Left in the Stock?

Zacks

2 years ago

Central Valley Community Bancorp (CVCY) Soars 6.4%: Is Further Upside Left in the Stock?

Apollo Tactical Income Fund Inc. Declares December 2023 Monthly Distribution of $0.133 Per Share

GlobeNewswire

2 years ago

Apollo Tactical Income Fund Inc. Declares December 2023 Monthly Distribution of $0.133 Per Share

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

PR Newswire

2 years ago

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Are Options Traders Betting on a Big Move in Cambium Networks (CMBM) Stock?

Zacks

2 years ago

Are Options Traders Betting on a Big Move in Cambium Networks (CMBM) Stock?

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

PR Newswire

2 years ago

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

Meridian Bank Ranked Top SBA Lender

GlobeNewswire

2 years ago

Meridian Bank Ranked Top SBA Lender

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

GlobeNewswire

2 years ago

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Noodles & Company (NASDAQ:NDLS) has caught the attention of institutional investors who hold a sizeable 44% stake

Simply Wall St.

2 years ago

Noodles & Company (NASDAQ:NDLS) has caught the attention of institutional investors who hold a sizeable 44% stake

GlobeNewswire

2 years ago

Veea to Become Publicly Traded Company via proposed Business Combination with Plum Acquisition Corp. I

Do These 3 Checks Before Buying Westwood Holdings Group, Inc. (NYSE:WHG) For Its Upcoming Dividend

Simply Wall St.

2 years ago

Do These 3 Checks Before Buying Westwood Holdings Group, Inc. (NYSE:WHG) For Its Upcoming Dividend

Is It Smart To Buy LCNB Corp. (NASDAQ:LCNB) Before It Goes Ex-Dividend?

Simply Wall St.

2 years ago

Is It Smart To Buy LCNB Corp. (NASDAQ:LCNB) Before It Goes Ex-Dividend?

Natural Gas Services Group, Inc. (NYSE:NGS) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Natural Gas Services Group, Inc. (NYSE:NGS) Q3 2023 Earnings Call Transcript

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Retail investors who hold 57% of ICZOOM Group Inc. (NASDAQ:IZM) gained 13%, insiders profited as well

Simply Wall St.

2 years ago

Retail investors who hold 57% of ICZOOM Group Inc. (NASDAQ:IZM) gained 13%, insiders profited as well

Latham Group, Inc. (NASDAQ:SWIM) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Latham Group, Inc. (NASDAQ:SWIM) Q3 2023 Earnings Call Transcript

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

GlobeNewswire

2 years ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

GlobeNewswire

2 years ago

Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination

Full House Resorts, Inc. (NASDAQ:FLL) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Full House Resorts, Inc. (NASDAQ:FLL) Q3 2023 Earnings Call Transcript

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Business Wire

2 years ago

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Full House Resorts Announces Strong Third Quarter Results

GlobeNewswire

2 years ago

Full House Resorts Announces Strong Third Quarter Results

Share on Social Networks: